This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Feb 19;170(4):JC20.

doi: 10.7326/ACPJ201902190-020.

Adding mirtazapine to ongoing SNRIs or SSRIs did not improve symptoms of treatment-resistant depression

Gregory E Simon

PMID: 30776809
DOI: 10.7326/ACPJ201902190-020

Comment

Adding mirtazapine to ongoing SNRIs or SSRIs did not improve symptoms of treatment-resistant depression

Gregory E Simon. Ann Intern Med. 2019.

. 2019 Feb 19;170(4):JC20.

doi: 10.7326/ACPJ201902190-020.

Author

Gregory E Simon

PMID: 30776809
DOI: 10.7326/ACPJ201902190-020

No abstract available

PubMed Disclaimer

Comment on

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
Kessler DS, MacNeill SJ, Tallon D, Lewis G, Peters TJ, Hollingworth W, Round J, Burns A, Chew-Graham CA, Anderson IM, Shepherd T, Campbell J, Dickens CM, Carter M, Jenkinson C, Macleod U, Gibson H, Davies S, Wiles NJ. Kessler DS, et al. BMJ. 2018 Oct 31;363:k4218. doi: 10.1136/bmj.k4218. BMJ. 2018. PMID: 30381374 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon